- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07940348
Supine Versus Prone Whole-Breast Radiotherapy in Thai Women After Breast-Conserving Surgery (SPAR-Breast)
Dosimetric Comparison of Supine Versus Prone Whole-Breast Radiotherapy in Thai Women After Breast-Conserving Surgery: A Prospective Paired Study
This study aims to compare two positions used for whole-breast radiation therapy in Thai women who have undergone breast-conserving surgery: lying on the back (supine) and lying face down (prone).
Radiation therapy after breast-conserving surgery helps reduce the risk of breast cancer returning. However, some radiation may reach nearby organs, particularly the heart and lungs. The position used during treatment may affect how much radiation these organs receive.
In this study, 24 women will undergo radiation treatment planning CT scans in both the supine and prone positions. Researchers will create a radiation treatment plan for each position and compare how well the plans cover the breast while minimizing radiation exposure to the heart and lungs. Each participant will receive actual radiation treatment in only one of the two positions, selected based on treatment planning results and clinical suitability.
The study will also assess patient comfort, positioning accuracy, treatment setup time, and treatment-related side effects.
The findings may help identify which patients are more likely to benefit from prone positioning and support individualized breast radiation treatment planning in Thai women.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is a prospective paired within-patient dosimetric study comparing supine and prone whole-breast radiotherapy in Thai women after breast-conserving surgery.
Each participant will undergo CT simulation in both the supine and prone positions. A three-dimensional conformal radiotherapy plan will be generated for each position using the same planning approach. The two plans will first be evaluated for acceptable target coverage. They will then be compared according to radiation exposure to organs at risk, with primary consideration given to the heart and ipsilateral lung and secondary consideration given to the contralateral lung and contralateral breast.
The treatment position used for actual radiotherapy will be selected using a predefined plan-comparison algorithm based on target coverage and organ-at-risk dose criteria. If both plans are otherwise comparable, patient preference may be used as a final decision factor. The participant will receive treatment in only one selected position.
The study will also explore whether anatomical characteristics, including chest wall and breast-related measurements, are associated with greater dosimetric benefit from prone positioning. Additional assessments include treatment setup time, positioning accuracy, patient comfort and preference, and treatment-related toxicity.
The study is intended to provide institution-specific data on individualized selection of breast radiotherapy position in Thai women rather than assuming that either supine or prone positioning is preferable for all patients.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Tanun Jitwatcharakomol, MD
- Numero di telefono: +66 90 962 3000
- Email: tanun.jit@mahidol.ac.th
Backup dei contatti dello studio
- Nome: Natawat Sukumtanakul, MD
- Numero di telefono: +66 90 985 6598
- Email: d.natawats@gmail.com
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologically confirmed breast carcinoma or ductal carcinoma in situ (DCIS)
- Status post breast-conserving surgery
- Planned adjuvant breast-only radiotherapy
- No indication for regional nodal irradiation
- Preoperative breast size corresponding to bra cup A-B, defined by the patient's preoperative bra size or a bust-minus-underbust circumference difference of <14 cm
- Age ≥18 years
Exclusion Criteria:
- Planned treatment using Deep Inspiration Breath Hold (DIBH)
- Bilateral breast cancer
- Previous radiotherapy to the ipsilateral breast
- Unable to tolerate either the prone or supine position
- Breast volume >750 cm³
- Pre-existing heart disease or lung disease
- Active connective tissue disease
- Pregnant or found to be pregnant
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Supine and Prone Whole-Breast Radiotherapy Planning
All participants will undergo CT simulation and treatment planning in both the supine and prone positions. The two plans will be compared for target coverage and radiation dose to organs at risk, including the heart and ipsilateral lung. Actual whole-breast radiotherapy will be delivered in only one selected position based on predefined plan-selection criteria and clinical suitability. |
Participants will undergo CT simulation in both supine and prone positions after breast-conserving surgery. Whole-breast radiotherapy plans will be generated for both positions using 3-dimensional conformal radiotherapy (3D-CRT). Target coverage and organ-at-risk dosimetric parameters will be compared between the two plans. The treatment position will be selected according to predefined target coverage and organ-at-risk criteria. Participants will receive actual radiotherapy in the selected position only. The prescribed whole-breast dose is 40 Gy in 15 fractions, with a simultaneous integrated boost to 48 Gy in selected patients. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mean Heart Dose in Supine Versus Prone Treatment Plans
Lasso di tempo: within 4 weeks after both CT simulations
|
Mean radiation dose to the heart, measured in Gray (Gy), will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. The mean heart dose will be compared between the two positions while maintaining acceptable target coverage. |
within 4 weeks after both CT simulations
|
|
Mean Ipsilateral Lung Dose in Supine Versus Prone Treatment Plans
Lasso di tempo: within 4 weeks after both CT simulations
|
Radiation dose to the lung on the same side as the treated breast will be assessed from the dose-volume histogram for both supine and prone treatment plans. Dosimetric parameters will include mean ipsilateral lung dose, and will be compared within the same participant while maintaining acceptable target coverage. |
within 4 weeks after both CT simulations
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
PTV_Eval V95 in Supine Versus Prone Treatment Plans
Lasso di tempo: within 4 weeks after both CT simulations
|
PTV_Eval V95, defined as the percentage of PTV_Eval receiving at least 95% of the prescribed dose, will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. PTV_Eval V95 will be compared between the two positions. The unit of measure is percentage (%). |
within 4 weeks after both CT simulations
|
|
Treatment time from initial setup to treatment completion
Lasso di tempo: within 4 weeks after treatment completion
|
Time required for patient positioning and setup until treatment is completed will be recorded and compared between the supine and prone positions. Time will be reported in minutes. |
within 4 weeks after treatment completion
|
|
translational X Positioning Accuracy
Lasso di tempo: within 4 weeks after treatment completion
|
Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational X axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm). |
within 4 weeks after treatment completion
|
|
translational Y Positioning Accuracy
Lasso di tempo: within 4 weeks after treatment completion
|
Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Y axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm). |
within 4 weeks after treatment completion
|
|
translational Z Positioning Accuracy
Lasso di tempo: within 4 weeks after treatment completion
|
Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Z axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm). |
within 4 weeks after treatment completion
|
|
Patient Satisfaction Score
Lasso di tempo: within 1 hours after both CT simulations, and within 1 hours after treatment completion
|
Patient satisfaction will be assessed using a study-specific questionnaire. Comfort and satisfaction will be rated using a 5-point Likert scale ranging from 1 to 5, with higher scores indicating greater comfort and satisfaction with the position. |
within 1 hours after both CT simulations, and within 1 hours after treatment completion
|
|
Radiation Therapist Satisfaction
Lasso di tempo: within 1 hours after treatment completion
|
Radiation therapist satisfaction with patient positioning will be assessed using a study-specific 5-point Likert satisfaction scale for the supine and prone positions. Scores range from 1 to 5, with higher scores indicating greater radiation therapist satisfaction with the positioning technique. |
within 1 hours after treatment completion
|
|
Acute Skin Toxicity using CTCAE Version 5.0 graing scale
Lasso di tempo: Weekly during radiotherapy for about 3 weeks and at 1 month after treatment completion
|
Acute radiation-related skin toxicity will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Radiation dermatitis will be graded from Grade 0 to Grade 5, with higher grades indicating greater severity of skin toxicity. |
Weekly during radiotherapy for about 3 weeks and at 1 month after treatment completion
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Tanun Jitwatcharakomol, MD, Mahidol University
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Carcinoma mammario in situ
- Neoplasie per sede
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Malattie della pelle
- Malattie del seno
- Carcinoma
- Neoplasie duttali, lobulari e midollari
- Carcinoma in situ
- Comportamento
- Malattie della pelle e del tessuto connettivo
- Comportamento sociale
- Neoplasie mammarie
- Carcinoma, intraduttale, non infiltrante
- Inganno
Altri numeri di identificazione dello studio
- 683/2569(IRB1)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .